Newer anticonvulsants: Lamotrigine, topiramate and gabapentin
Authors:
- Lewis B. HolmesLHLewis B. Holmes
- Sonia Hernandez‐DiazSHSonia Hernandez‐Diaz
- 22 June 2012
- journal article
- research article
- Published by Wiley in Birth Defects Research Part A: Clinical and Molecular Teratology
- Vol. 94 (8) , 599-606
Abstract
BACKGROUND The second generation antiepileptic drugs (AEDs), which include lamotrigine, topiramate, and gabapentin, have been introduced during the past 20 years. Because the newer AEDs differ in their pharmacokinetics from the first generation AEDs, it is hoped that the second generation AEDs will be less teratogenic. METHODS The findings in pregnancy cohorts and case‐control studies concerning lamotrigine, topiramate and gabapentin‐exposed pregnancies have been analyzed. RESULTS The rate of all malformations in lamotrigine monotherapy‐exposed pregnancies has been between 2.0 and 5.6%, in comparison to baseline rates of 1.1 to 3.6% in two unexposed comparison groups. Compared to reference populations, a higher risk (0.4%) of isolated oral clefts has been observed in one cohort of 1562 lamotrigine‐exposed pregnancies, but the risk was lower (0.1%) in other studies. In topiramate‐exposed pregnancies, the rate of all malformations has been 4.2 to 4.9%, with an increase in oral clefts with and without other anomalies. The limited information available now for gabapentin has shown no evidence of teratogenicity. Concerning other developmental effects of these drugs, young children exposed to lamotrigine in utero have shown no deficits in cognitive function. Prenatal exposure to topiramate has been associated with an elevated frequency of small size for gestational age newborns. CONCLUSIONS The information available suggests an increased risk of oral clefts in infants exposed to topiramate, and perhaps lamotrigine, early in pregnancy, and of growth retardation for topiramate‐exposed infants. Larger sample sizes are needed to clarify the questions that have been raised. Birth Defects Research (Part A) 94:599–606, 2012.Keywords
This publication has 47 references indexed in Scilit:
- Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension studyThe American Journal of Clinical Nutrition, 2012
- Foetal antiepileptic drug exposure and verbal versus non-verbal abilities at three years of ageBrain, 2011
- A Comparison of the Pharmacokinetics and Pharmacodynamics of Pregabalin and GabapentinClinical Pharmacokinetics, 2010
- Teratogenic effects of antiepileptic drugsExpert Review of Neurotherapeutics, 2010
- Practice Parameter update: Management issues for women with epilepsy—Focus on pregnancy (an evidence-based review): Obstetrical complications and change in seizure frequency [RETIRED]Neurology, 2009
- Cognitive Function at 3 Years of Age after Fetal Exposure to Antiepileptic DrugsNew England Journal of Medicine, 2009
- Pharmacokinetics and Therapeutic Drug Monitoring of Newer Antiepileptic Drugs During Pregnancy and the PuerperiumClinical Pharmacokinetics, 2007
- Pharmacokinetic Variability of Newer Antiepileptic DrugsClinical Pharmacokinetics, 2006
- The correlation of deficits in IQ with midface and digit hypoplasia in children exposed in utero to anticonvulsant drugsThe Journal of Pediatrics, 2005
- Malformations Due to Presumed Spontaneous Mutations in Newborn InfantsNew England Journal of Medicine, 1989